Galapagos N.V. (GLPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos N.V. (GLPG) has a cash flow conversion efficiency ratio of -0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-62.61 Million ≈ $-73.19 Million USD) by net assets (€2.88 Billion ≈ $3.36 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galapagos N.V. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Galapagos N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Galapagos N.V. total liabilities for a breakdown of total debt and financial obligations.
Galapagos N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos N.V. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhengzhou GL Tech Co Ltd
SHE:300480
|
-0.004x |
|
NFI Group Inc
TO:NFI
|
0.202x |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
0.002x |
|
Calibre Mining Corp
TO:CXB
|
0.053x |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
0.047x |
|
Sanquan Food Co Ltd
SHE:002216
|
0.057x |
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
0.004x |
|
Hugel Inc
KQ:145020
|
0.066x |
Annual Cash Flow Conversion Efficiency for Galapagos N.V. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Galapagos N.V. from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see Galapagos N.V. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +23.93% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-405.97 Million ≈ $-474.62 Million |
-0.145x | +26.71% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | +200.51% |
| 2015-12-31 | €365.00 Million ≈ $426.72 Million |
€-114.59 Million ≈ $-133.97 Million |
-0.314x | +14.35% |
| 2014-12-31 | €206.13 Million ≈ $240.99 Million |
€-75.56 Million ≈ $-88.33 Million |
-0.367x | -11835.82% |
| 2013-12-31 | €167.14 Million ≈ $195.40 Million |
€522.00K ≈ $610.27K |
0.003x | -99.42% |
| 2012-12-31 | €118.45 Million ≈ $138.48 Million |
€64.10 Million ≈ $74.94 Million |
0.541x | +634.28% |
| 2011-12-31 | €118.38 Million ≈ $138.39 Million |
€-11.99 Million ≈ $-14.02 Million |
-0.101x | +19.01% |
| 2010-12-31 | €148.51 Million ≈ $173.62 Million |
€-18.57 Million ≈ $-21.71 Million |
-0.125x | -316.03% |
| 2009-12-31 | €108.88 Million ≈ $127.29 Million |
€6.30 Million ≈ $7.37 Million |
0.058x | +159.47% |
| 2008-12-31 | €84.32 Million ≈ $98.58 Million |
€-8.21 Million ≈ $-9.60 Million |
-0.097x | -2687.95% |
| 2007-12-31 | €98.63 Million ≈ $115.30 Million |
€371.00K ≈ $433.74K |
0.004x | +104.43% |
| 2006-12-31 | €109.54 Million ≈ $128.07 Million |
€-9.31 Million ≈ $-10.88 Million |
-0.085x | -33.68% |
| 2005-12-31 | €61.14 Million ≈ $71.47 Million |
€-3.89 Million ≈ $-4.54 Million |
-0.064x | +75.68% |
| 2004-12-31 | €10.37 Million ≈ $12.12 Million |
€-2.71 Million ≈ $-3.17 Million |
-0.261x | -- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more